Claims for Patent: 11,078,288

Summary for Patent: 11,078,288

Title:	Methods and compositions for treating tumor diseases
Abstract:	The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
Inventor(s):	Beltran Pedro J., Calzone Frank J., Friberg Gregory, Haqq Christopher, Tolcher Anthony W.
Assignee:	Amgen Inc.
Application Number:	US15955304
Patent Claims:

Details for Patent 11,078,288

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	March 25, 2003		2038-04-17
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	July 31, 2014		2038-04-17
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2038-04-17
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	September 27, 2006		2038-04-17